Faeth Therapeutics, Inc. Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount
Faeth Therapeutics, Inc. (FTH) had Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount of $62.20 million as of 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions · last filed 2026-08-04
- 2026-06-30: Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount $62.20M.
- 2026-03-31: Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount $57.40M.
- 2025-12-31: Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount $600.00K.
- 2025-09-30: Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount $800.00K.
| Period end | Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount |
|---|---|
| 2026-06-30 | $62.20M 10-Q · filed 2026-08-04 |
| 2026-03-31 | $57.40M 10-Q · filed 2026-05-15 |
| 2025-12-31 | $600.00K 10-K · filed 2026-03-30 |
| 2025-09-30 | $800.00K 10-Q · filed 2025-11-14 |
| 2025-06-30 | $1.10M 10-Q · filed 2025-08-05 |
| 2025-03-31 | $1.30M 10-Q · filed 2025-05-06 |
| 2024-12-31 | $1.50M 10-K · filed 2026-03-30 |
| 2024-09-30 | $2.00M 10-Q · filed 2024-11-14 |
| 2024-06-30 | $2.70M 10-Q · filed 2024-08-06 |
| 2024-03-31 | $3.80M 10-Q · filed 2024-05-09 |
| 2023-12-31 | $4.10M 10-K · filed 2025-03-28 |
| 2023-09-30 | $5.10M 10-Q · filed 2023-11-07 |
| 2023-06-30 | $5.90M 10-Q · filed 2023-08-03 |
| 2023-03-31 | $7.60M 10-Q · filed 2023-05-09 |
| 2022-12-31 | $8.80M 10-K · filed 2024-02-29 |
| 2022-09-30 | $12.10M 10-Q · filed 2022-11-08 |
| 2022-06-30 | $13.40M 10-Q · filed 2022-08-09 |
| 2022-03-31 | $15.20M 10-Q · filed 2022-05-10 |
| 2021-12-31 | $16.00M 10-K · filed 2023-03-29 |
| 2021-09-30 | $19.70M 10-Q · filed 2021-11-10 |
| 2021-06-30 | $21.00M 10-Q · filed 2021-08-11 |
| 2021-03-31 | $21.40M 10-Q · filed 2021-05-13 |
| 2020-12-31 | $5.90M 10-K · filed 2022-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |